DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.
Ewa CendrowiczLisa JacobShirley GreenwaldAmi TamirIris PeckerRinat TabakmanLucy GhantousLiat TamirRoy KahnJasmine AvichzerAlexandra AroninShira AmsiliElina Zorde-KhvalevskyYosi GozlanMartijn VlamingGerwin HulsTom van MeertenMichal Elhalel DranitzkiAdam Foley-ComerYaron PeregAmnon PeledAyelet ChajutEdwin BremerPublished in: Journal of experimental & clinical cancer research : CR (2022)
DSP107 effectively (re)activated innate and adaptive anticancer immune responses and may be of therapeutic use alone and in combination with rituximab for the treatment of DLBCL patients.